NasdaqGS - Nasdaq Real Time Price
USD
Praxis Precision Medicines, Inc. (PRAX)
311.99
-7.29
(-2.28%)
As of 12:34:47 PM EDT. Market Open.
Trade PRAX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for PRAX
- Previous Close
319.28 - Open
308.97 - Bid 227.78 x 200
- Ask 400.75 x 200
- Day's Range
308.51 - 320.85 - 52 Week Range
26.70 - 356.00 - Volume
142,870 - Avg. Volume
493,804 - Market Cap (intraday)
8.689B - Beta (5Y Monthly) 3.01
- PE Ratio (TTM)
-- - EPS (TTM)
-13.47 - Earnings Date (est.) Apr 30, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
617.62
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
praxismedicines.comRecent News: PRAX
View More
Performance Overview: PRAX
Trailing total returns as of 4/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
PRAX
5.85%
S&P 500 (^GSPC)
4.22%
1-Year Return
PRAX
740.72%
S&P 500 (^GSPC)
15.62%
3-Year Return
PRAX
2,470.99%
S&P 500 (^GSPC)
59.56%
5-Year Return
PRAX
32.58%
S&P 500 (^GSPC)
63.11%
Earnings Trends: PRAX
View MoreAnalyst Insights: PRAX
View MoreStatistics: PRAX
View MoreValuation Measures
As of 4/1/2026
-
Market Cap
8.89B
-
Enterprise Value
8.29B
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
953.14
-
Price/Book (mrq)
10.13
-
Enterprise Value/Revenue
1.22k
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-28.69%
-
Return on Equity (ttm)
-45.83%
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
-303.27M
-
Diluted EPS (ttm)
-13.47
Balance Sheet and Cash Flow
-
Total Cash (mrq)
599.33M
-
Total Debt/Equity (mrq)
0.01%
-
Levered Free Cash Flow (ttm)
-146.25M
Compare To: PRAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: PRAX
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
